Introduction
============

Overweight is among the leading modifiable risk factors for the development of cardiovascular disease (CVD) ([@r1]). Current guidelines recommend weight loss through dietary measures and increased physical activity. While these provisions may suffice in an otherwise healthy population ([@r2]), subjects with relevant comorbidities such as arterial hypertension, diabetes mellitus, or diseases aggravated by overweight may require additional pharmacological treatment.

WS 1442, the active ingredient of the herbal medicinal product Crataegutt^®^ (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany), is a dry extract from *Crataegus* leaves with flowers (4-6.6:1), extraction solvent: ethanol 45% (w/w). The extract is adjusted to 17.3%-20.1% oligomeric procyanidins and contains flavonoids ([@r3]). WS 1442 has been registered in several European countries as a phytopharmaceutical medicinal product for the treatment of heart failure (HF) (stage II in the New York Heart Association classification), with a recommended daily dose of up to 900 mg.

Endothelial dysfunction (ED) is an early marker for the development of CVD that can be detected before the onset of structural changes to the vessel wall ([@r4]). WS 1442 causes vasorelaxation by an endothelium-dependent and nitric oxide-mediated mechanism ([@r5], [@r6]), by supporting endothelium-derived hyperpolarizing factor-mediated vasorelaxation, and by reducing endothelium-dependent contractile responses ([@r7]), and reduces stiffness of the endothelial surface layer ([@r8]). It is assumed that an increased coronary blood flow, reduced ED, inhibition of lipid oxidation and anti-inflammatory properties contribute to its cardioprotective effects ([@r9]). Owing to these pharmacological properties ([@r6], [@r8]) and in combination with its favorable safety profile ([@r10]-[@r12]), WS 1442 may have beneficial effect on ED and lipid parameters in overweight but otherwise healthy individuals who are at an increased cardiovascular risk (CVR) related to atherosclerosis.

As marketing authorizations for *Crataegus* extract preparations (including WS 1442) as medicinal products have been granted based on monographs and scientific literature ([@r13], [@r14]), no data on healthy volunteers have been available to date.

Physical exercise has been shown to exert beneficial effects on elevated serum lipids, diabetes mellitus and arterial hypertension. Furthermore, morphological and functional parameters such as endothelial (dys)function may be improved. In a healthy population, increased CVR resulting from overweight may be ameliorated through dietary measures in combination with physical exercise, even when the individual's weight is actually not reduced ([@r15]-[@r17]). Physical exercise is therefore an ideal 'control group' to compare the effects of WS 1442 with an intervention already shown to exhibit beneficial effects on ED and lipid metabolism.

We therefore tested two hypotheses; thus, the primary hypothesis of this randomized pilot study was to obtain first information on the safety of two different doses of WS 1442 in overweight but otherwise healthy volunteers. Secondly, we aimed at exploring the effects of WS 1442 on the measures of endothelial function in comparison to physical exercise the benefits of which in maintaining or restoring endothelial function have already been demonstrated ([@r15]-[@r17]).

Materials and Methods
=====================

Design
------

This was a single-center, randomized, phase I pilot study with four parallel groups comparing two dosages of WS 1442 and two intensities of physical exercise over a period of 12 weeks. Treatments were double-blind concerning comparison between WS 1442 900 mg/day and 1,800 mg/day, and open-label for comparison between WS 1442 and physical exercise. Due to the exploratory concept of the trial, no pre-specified hypotheses were tested.

Ethics
------

The study was performed under consideration of the principles of the Good Clinical Practice and Declaration of Helsinki and registered in clinicaltrials.gov (NCT00982501). The independent ethics committee of the federal State of Salzburg, Austria, reviewed and approved the trial protocol (registration no. 415-E912/14-2008). Informed consent was obtained from all subjects.

Subjects
--------

Participants were overweight (body mass index, BMI: 25.0-29.9 kg/m^2^) but otherwise healthy volunteers without regular physical exercise training during the last three months before enrolment. Male and female subjects aged 45-75 years, with blood pressure ≤140/90 mm Hg, normal resting electrocardiogram (ECG) and normal ECG stress test were eligible for inclusion. The main exclusion criteria were regular intake of any medication (except for oral contraceptives), echocardiographic evidence of any cardiac disease, FEV~1~/FVC ratio \<70%, clinically important physical or psychiatric diseases, abnormal urinalysis including microalbuminuria, and nicotine consumption. Concomitant intake of other hawthorn preparations or dietary supplements with a potential influence on the study outcome measures was prohibited.

The study was performed at the Institute of Sports Medicine, Prevention and Rehabilitation of the Paracelsus Medical University in Salzburg, Austria. Advertisements in local newspapers were used for subject recruitment.

Interventions
-------------

WS 1442 was available in film-coated tablets containing 450 mg extract. Treatment group 1 received one WS 1442 tablet and one placebo tablet b.i.d. (WS-standard; total daily dose: 900 mg), and group 2 received two WS 1442 tablets b.i.d. (WS-double; total daily dose: 1,800 mg). The tablets were to be taken unchewed in the morning and in the evening with some water. Placebo and WS 1442 tablets were identical in size and appearance.

The subjects in the exercise training did not receive any investigational drugs (including placebo) but practiced Nordic walking (NW) for 2x30 minutes (group 3, light exercise; NW-low) or for 4x45 minutes *per* week (group 4, moderate exercise; NW-high). Eligible subjects were randomized to study groups using an allocation ratio of 1:1:1:1 without further stratification. The random code was generated by a member of the manufacturer's Biometrics Department otherwise not involved in the study, using a validated random number generator (RCODE). Upon randomization, each subject received the lowest available random number. An authorized investigator enrolled the participants. The number was attached to a sealed envelope that included a document showing either the type of exercise or medication number, and concealed the intervention until assignment. After random code assignment, distinction between drug treatment and NW, and between the NW-low and NW-high conditions was open for study participants and investigational staff, whereas distinction between WS-low and WS-high remained double-blind.

The subjects in the exercise training groups had to participate in regular NW workouts guided by instructors. We used NW as exercise intervention due to the well-documented applicability in untrained participants ([@r18]). Subjects received walking poles and a heart rate monitor and were introduced into their use. Exercise training was performed at \>70% of the maximum heart rate achieved during treadmill test, representing the heart rate corresponding to approximately 3-4 mmol/L of blood lactate.

Study schedule
--------------

Screening and baseline examinations were performed to assure the subject eligibility for the trial including medical history assessments, anthropometric measurements, physical status, resting ECG, echocardiography, exercise stress testing ([@r19]), spirometry, and safety laboratory tests including urinalysis. After randomization during the baseline visit, eligible subjects underwent 12-week intervention, with follow-up visits at the end of weeks 6 and 12. Vital signs were assessed at all visits, and laboratory tests were repeated at the final visit. At baseline and during the final visit, treadmill ergometry with lactate testing was performed and endothelial function was assessed. During all visits, adverse events (AEs) were recorded.

Outcomes
--------

Endothelial function was assessed noninvasively by determining the Reactive Hyperemia Index (RHI) using an Endo-Pat2000 device (Itamar Medical Ltd., Israel). The test is based on endothelium-mediated relaxation of arteries at the distal phalanx of a finger as a reaction to five-minute occlusion of the brachial artery, using a standard blood pressure cuff. RHI is defined as the ratio between the peripheral arterial tone before and after the occlusion. The score is significantly correlated with CVR factors ([@r20], [@r21]) and has been validated as a predictor of cardiovascular outcomes ([@r22]). It has been shown to be sensitive to change induced by treatment ([@r23]). A cut-off value of 1.67 provides 82% sensitivity and 77% specificity for diagnosing coronary ED ([@r21]). The device also computes the Augmentation Index (AI), a measure of arterial stiffness related to age and atherosclerosis ([@r24]).

Treadmill testing was used to determine the 2 mmol/L and 4 mmol/L lactate thresholds (aerobic threshold and anaerobic threshold) according to the method described by Heck *et al*. ([@r25]) and maximum individual performance (heart rate). Participants were instructed to exercise until subjective exhaustion or a systolic blood pressure ≥250 mm Hg was reached ([@r19]). Treadmill exercise commenced at a speed of 2 km/h and slope of 1.5% and was increased to 4 and 6 km/h during the second and third step, respectively. In the fourth step, the slope was increased to 5%, with additional increases by 5% during each subsequent step. The duration of each step was 3 minutes. Lactate concentrations were determined by blood sampling from the earlobe before the start of treadmill exercise and at the end of each step. Further samples were taken at 1, 3 and 5 minutes after exercise cessation.

Additionally, quantitative measurement of endothelial progenitor cells (EPCs) related to the progression of CVD due to their role in plaque formation, vasculogenesis, angiogenesis and other pathways ([@r26]) was conducted. Decreased numbers of EPCs were shown to correlate with CVR factors, disease progression and prognosis of coronary artery disease ([@r27]). Peripheral blood mononuclear cells were separated *via* density gradient centrifugation and incubated with specific antibodies (10 µL *per* 10^7^ cells) as follows: CD3 (fluorescein isothiocyanate; BD Pharmingen), CD34 (phycoerythin; BD Pharmingen), CD45 (peridinin chlorophyll protein; BD Pharmingen) and KDR/anti-VEGFR2 (allophycocyanin, mouse IgG1, R & D Systems). Acquisition was performed on a FACSCalibur^®^ cytometer (Becton Dickinson, Belgium). Analysis and gating was performed using FlowJo 9.0.1 (Tree Star, Inc., Ashland, OR, USA) software for Macintosh. Lymphocyte population was plotted in a CD45/sideward scatter plot, and CD45+ cells were selected for further analysis. To rule out common lymphocyte populations and to increase the sensitivity for EPCs, CD3 positive cells were excluded using a CD45/CD3 plot. The numbers and percentages of triple positive cells for CD45+, CD34+ and KDR+ were determined. Altogether, cells positive for CD45+/CD34+/KDR+ and negative for CD3- were defined to be EPCs. To homogenize the sample size, the first 10^6^ events were recorded and analyzed. For better visualization of cells with low numbers, logarithmic transformation (log 10) was performed to determine absolute EPC level values ([@r28]).

Lipid profiles of the study subjects were assessed using fasting venous blood samples. Triglycerides, HDL-cholesterol, and total cholesterol were analyzed using Roche/Hitachi Systems (Roche Diagnostics GmbH, Mannheim, Germany); LDL-cholesterol was analyzed using Cobas Integra 400/700/800 for direct measurement of LDL-cholesterol.

Statistics
----------

In accordance with the concept of the trial as an exploratory pilot study, descriptive statistical analyses were performed and no formal hypotheses were tested. For outcomes related to ED, missing data at treatment end were replaced by the values obtained at week 6 if available. All analyses were based on all subjects who were randomized and treated.

A total sample size of 60 subjects was planned to obtain at least 4x12 subjects for ED evaluation. The sample size was chosen to obtain an acceptable precision on summary statistics for the outcomes of interest ([@r29]) for further study planning.

Results
=======

Study participants
------------------

A detailed and structured telephone interview was carried out with 417 subjects responding to the advertisements. Based on the inclusion and exclusion criteria, we screened 79 subjects and 60 subjects were then randomized (15 *per* group), whereas 19 did not meet the inclusion criteria or met an exclusion criterion. One subject in the WS-standard group revoked informed consent before the first administration of the investigational treatment and was therefore excluded from all analyses. One subject in each group was withdrawn prematurely during randomized treatment due to an AE; however, all events leading to premature termination were unrelated to the investigational treatments.

All treated subjects were analyzed for safety and pharmacodynamic measures (ED), lipid profile and exercise capacity ([Fig. 1](#f1){ref-type="fig"}).

![Distribution of study subjects according to intervention groups. The numbers of subjects with relevant protocol deviations were 6/14, 3/15, 5/15 and 3/15 for WS-standard, WS-double, NW-low and NW-high, respectively. Relevant violations were premature withdrawal during the first 10 weeks of randomized treatment (1/1/1/1 subjects), an inappropriate FEV1/FVC ratio at inclusion (0/1/0/0), non-adherence to the treatment or visit schedule (0/0/1/1), missing pharmacodynamic examinations (2/0/1/1), and use of prohibited concomitant medication (4/1/2/0).](acc-58-604-f1){#f1}

[Table 1](#t1){ref-type="table"} presents baseline characteristics of study subjects. Individual baseline lipid values were either within the applicable reference ranges or considered to be clinically irrelevant. The mean drug compliance was 98.7% and 97.8% of tablets taken relative to the prescribed amount for WS-standard and WS-double, respectively. The mean exercise attendance in both NW groups was 93%.

###### Baseline characteristics and pharmacodynamic measures

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baseline characteristic                                 WS 1442 900 mg/d (n=14)   WS 1442 1,800 mg/d (n=15)   Light exercise (n=15)   Moderate exercise (n=15)   
  ------------------------------------------------------- ------------------------- --------------------------- ----------------------- -------------------------- -------------------
  Sex: female                                             8 (57.1%)                 11 (73.3%)                  12 (80.0%)              7 (46.7%)                  

  Age (years)                                             55.8±7.2                  53.4±6.5                    54.5±6.8                53.9±6.1                   

  Body mass index (kg/m^2^)                               27.7±1.2                  27.7±1.5                    27.3±1.4                27.8±1.5                   

  EndoPAT® measurements:                                                                                                                                           

  Reactive hyperemia index (RHI)                          Baseline                  1.97±0.66                   1.91±0.57               2.21±0.52                  2.12±0.58

  Subjects with RHI \<1.67                                Baseline                  7 (50.0%)                   8 (53.3%)               1 (6.7%)                   5 (33.3%)

  Reactive hyperemia index (RHI)                          Week 12 -- Baseline       0.05±0.70                   -0.15±0.57              -0.23±0.49                 -0.12±0.82

  RHI: only subjects with baseline RHI \<1.67             Week 12 -- Baseline       0.30±0.35 (n=7)             0.24±0.41 (n=8)         0.34 (n=1)                 0.28±0.43 (n=5)

  Any RHI improvement\*                                   Week 12 -- Baseline       9 (64.3%)                   5 (33.3%)               5 (33.3%)                  6 (40.0%)

  Augmentation index (AI) (%)                             Baseline                  18.18±15.05                 15.59±25.50             15.76±18.04                15.50±12.66

  AI (%)                                                  Week 12 -- Baseline       -1.56±10.55                 1.14±15.62              4.60±18.32                 3.27±14.10

  Any AI improvement\*\*                                  Week 12 -- Baseline       7 (50.0%)                   8 (53.3%)               4 (26.7%)                  6 (40.0%)

  Lipid profile:                                                                                                                                                   

  Cholesterol\                                            Screening                 220.9±28.1 (n=14)           219.2±42.4 (n=15)       220.1±40.5 (n=15)          206.6±40.4 (n=15)
  (ref: 150-220 mg/dL)                                                                                                                                             

  Week 12 -- Screening                                    -5.9±25.0 (n=13)          -0.8±23.1 (n=15)            -6.7±30.3 (n=14)        -0.1±16.8 (n=14)           

  Triglycerides\                                          Screening                 133.5±70.6 (n=14)           133.7±79.7 (n=15)       90.4±23.3 (n=15)           110.7±48.5 (n=15)
  (ref: 50-200 mg/dL)                                                                                                                                              

  Week 12 -- Screening                                    -31.8±42.7 (n=13)         -14.5±66.1 (n=15)           0.5±26.5 (n=14)         16.6±74.7 (n=14)           

  HDL-cholesterol (ref: female 48-70; male 40-60 mg/dL)   Screening                 64.1±14.0 (n=14)            61.4±16.2 (n=15)        65.9±14.3 (n=15)           64.0±16.5 (n=15)

  Week 12 -- Screening                                    3.2±8.5 (n=13)            1.1±7.5 (n=15)              -3.1±10.3 (n=14)        1.2±4.6 (n=14)             

  LDL-cholesterol\                                        Screening                 132.7±22.9 (n=13)           132.4±43.5 (n=15)       136.1±33.5 (n=15)          120.5±37.5 (n=15)
  (ref: 50-150 mg/dL)                                                                                                                                              

  Week 12 -- Screening                                    -5.2±24.1 (n=12)          -0.2±20.1 (n=15)            -3.7±26.4 (n=14)        -4.7±21.1 (n=14)           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are numbers (%) of subjects, or means ± SD, last observation carried forward. There were more females in the WS-double and NW-low groups than in the remaining groups; otherwise, there were no systematic group differences in clinical data, current physical status, vital signs and laboratory measures; \*subjects with changes in RHI \>0; \*\*subjects with changes in AI \<0.

Pharmacodynamic effects
-----------------------

Regarding endothelial function, subjects randomized to WS 1442 exhibited lower (i.e. less favorable) baseline mean RHI values, and a higher percentage of these subjects were at an increased CVR (RHI \<1.67), as compared with NW-groups. However, the mean baseline augmentation indices were comparable and all treatment groups showed elevated baseline augmentation index mean values.

During the study period, subjects in the WS-standard group showed numerical improvements of RHI and AI, whereas all other groups showed deteriorations of the respective parameters ([Table 1](#t1){ref-type="table"}). However, in all groups, subjects with baseline RHI \<1.67 exhibited mean RHI improvements by 17%-22% as compared to their baseline values. The percentage of subjects with any RHI improvement during randomized treatment was highest in WS-standard group followed by NW-high group. Regarding AI change, the highest percentage of subjects with improvement was recorded in the WS-double group followed by WS-standard group.

At baseline, the number of EPCs was lower in subjects randomized to WS-standard and WS-double (log scale: 0.88±0.56 and 0.82±0.65) compared to NW-low and NW-high (0.95±0.53 and 0.91±0.49). Subjects receiving WS-standard showed the largest numerical increase of EPC counts by 0.66±0.74 log units; all other groups exhibited increases by less than 0.4 SD log units.

During treadmill testing ([Table 2](#t2){ref-type="table"}), the subjects randomized to NW-high showed greatest improvements of all treatment groups, with the mean increase in workload increments *versus* baseline of 0.6±0.5 steps and increase in exercise time of 1.1±1.4 minutes. This was accompanied by elevations of the aerobic/anaerobic thresholds regarding both workload increments and exercise time. The subjects randomized to NW-low showed similar but less pronounced effects. In the subjects treated with WS 1442, exercise tolerance remained essentially unchanged.

###### Treadmill ergometry test: baseline values and increase from baseline to the end of randomized treatment (values are means±SD and subjects with valid test results \[n\])

  ------------------------------------------------------------------------------------------------------------------------------------
                                              WS 1442 900 mg/d   WS 1442 1,800 mg/d   Light exercise   Moderate exercise   
  ------------------------------------------- ------------------ -------------------- ---------------- ------------------- -----------
  Workload increments\                        Baseline           6.0±0.9\             5.8±0.8\         5.6±0.9\            6.1±0.6\
  \[increment steps\]                                            (n=14)               (n=15)           (n=15)              (n=15)

  Week 12 -- Baseline                         0.2±0.6\           0.0±0.4\             0.4±0.5\         0.6±0.5\            
                                              (n=13)             (n=14)               (n=14)           (n=14)              

  Exercise time \[min\]                       Baseline           17.0±2.5\            15.5±2.1\        15.4±2.2\           17.4±1.6\
                                                                 (n=14)               (n=15)           (n=15)              (n=15)

  Week 12 -- Baseline                         0.1±1.2\           -0.1±1.3\            0.6±0.8\         1.1±1.4\            
                                              (n=13)             (n=14)               (n=14)           (n=14)              

  Lactate threshold at 2 mmol/L - workload    Baseline           3.1±0.6\             2.6±1.0\         2.7±0.7\            3.1±0.7\
                                                                 (n=14)               (n=15)           (n=15)              (n=15)

  Week 12 -- Baseline                         0.2±0.8\           0.2±0.6\             0.1±0.8\         0.8±0.4\            
                                              (n=13)             (n=14)               (n=14)           (n=14)              

  Lactate threshold at 4 mmol/L -- workload   Baseline           4.2±0.7\             3.8±0.8\         3.9±0.6\            4.3±0.8\
                                                                 (n=14)               (n=15)           (n=15)              (n=15)

  Week 12 -- Baseline                         0.2±0.7\           0.1±0.5\             0.0±0.4\         0.6±0.5\            
                                              (n=13)             (n=14)               (n=14)           (n=14)              
  ------------------------------------------------------------------------------------------------------------------------------------

Safety and tolerability
-----------------------

The percentages of subjects with any AE during the study period were similar in all treatment groups except for NW-low, where fewer participants reported such events ([Table 3](#t3){ref-type="table"}). Most AEs were symptoms of the musculoskeletal system (e.g., arthralgia, back pain) or trivial infections. Four subjects exposed to WS 1442 had a total of seven events (arthralgia, chest discomfort, diarrhea, forehead headache, abdominal fullness, charley horse and tinnitus), in which a causal relationship with the investigational treatment was considered unlikely; in all other cases, causal relationship was excluded. Four of the seven events with unlikely causal relationship were observed in one patient. One serious AE was observed in the WS-double group (premature termination of the study to undergo a pre-planned umbilical hernia repair); therefore, causal relationship with the investigational treatment could be excluded. Individual vital signs and safety laboratory measures in all treatment groups were uneventful except for abnormal values that were attributable to concomitant diseases reported as AEs.

###### Adverse events during randomized treatment

  --------------------------------------------------------------------------------------------------------------------------------------------
                                                               WS 1442 900 mg/d\   WS 1442 1,800 mg/d\   Light\           Moderate exercise\
                                                               (n=14)              (n=15)                exercise\        (n=15)
                                                                                                         (n=15)           
  ------------------------------------------------------------ ------------------- --------------------- ---------------- --------------------
  Number of subjects with any adverse events (%)               11 (78.6%)          12 (80.0%)            11 (73.3%)       8 (53.3%)

  Total number of adverse events                               16                  24                    14               17

  Causal relationship of adverse events to study medication:                                                              

    No. of events with no relationship                         14                  19                    Not applicable   Not applicable

    No. of events with causal relationship unlikely            2                   5                     Not applicable   Not applicable
  --------------------------------------------------------------------------------------------------------------------------------------------

During randomized treatment, serum triglycerides decreased within the normal range in subjects receiving WS 1442 but not in NW groups ([Table 1](#t1){ref-type="table"}). In addition, subjects randomized to WS 1442 showed an increase in HDL-cholesterol that was not seen in the light exercise condition. There was a slight decrease within the normal range in LDL-cholesterol in all groups.

Discussion
==========

This was the first systematic investigation of safety and effects of the *Crataegus* extract WS 1442 in overweight, otherwise healthy volunteers. Results regarding tolerability and safety of the extract were not indicative of any previously unknown risks associated with the product. They therefore support the favorable safety profile of WS 1442 as previously observed in patients with HF ([@r10]-[@r12]). This applies to the recommended and marketed dose of 900 mg/day, as well as to the double dose of 1,800 mg/day. The study did not show any signal that subjects in WS-double group might be at an appreciably higher risk of AEs than those in WS-standard group. However, the validity of this interpretation is limited by the small sample size of this exploratory pilot study.

The baseline lipid profiles of most study subjects were within the normal limits, and any elevated values were considered to be clinically irrelevant. Participants randomized to WS-standard showed further decreases of triglycerides, which were accompanied by increases in HDL-cholesterol. These observations are consistent with the findings in animal models ([@r30]) and patients with chronic, stable HF of NYHA class III ([@r31], [@r32]). They therefore justify further investigations of the lipid lowering effects of WS 1442. No changes in lipid profiles were observed in NW groups.

All subjects with baseline ED showed an average RHI increase during intervention, whereas the mean RHI remained essentially unchanged throughout the study period in those with normal baseline endothelial function. As more subjects with impaired endothelial function were randomized to WS 1442, the mean RHI increased in these groups to near normal values, whereas RHI in the NW groups was normal already at baseline and remained so throughout the study. The mean EPC counts increased in all study groups throughout the intervention period, with the most pronounced changes observed in the WS-standard group. These results indicated that subjects who were at an increased CVR due to overweight and inactivity, notably those in whom limitations of endothelial function were already measurable, might benefit from treatment with WS 1442 through improvement of important functional markers, including RHI normalization. However, the study did not support an additional benefit of WS 1442 1,800 mg/day over the 900 mg/day dosage in the investigated sample, meaning that we did not find a dose dependent effect of WS 1442. Yet, this finding has to be interpreted with caution because our study was underpowered to answer such a research question. Further adequately powered studies could clarify this interesting issue.

Physical exercise training has been shown to improve ED ([@r15], [@r16], [@r33]-[@r35]). NW was therefore chosen in this study as an active control with proven, well-documented efficacy in the population of interest, in order to obtain an 'anchor' for the effects to be expected from WS 1442 in the same indication. Although it is quite unfortunate that this comparison was affected by coincidental baseline imbalance, our results nevertheless indicated that WS 1442 might induce effects on ED and EPCs similar to those of exercise training ([@r17], [@r36]). This interpretation is, however, only hypothesis-generating and requires confirmation in a larger study.

Unlike WS 1442, NW had beneficial effects on exercise capacity, the most predictive single parameter for cardiovascular events ([@r37]). Therefore, the increase in exercise capacity might be clinically most significant of the changes observed, with the highest impact on CVR. A major problem with the promotion of exercise training is poor long-term compliance ([@r38]). In our study, two of the 30 subjects in the NW groups withdrew from the intervention while all other subjects in these groups (93%) completed all training sessions and exercised with appropriate heart rates. Compliance was therefore much higher than in the HF-ACTION trial ([@r39]), where 84% of the patients were compliant during the initial 36 supervised sessions while a decrease to 62% at one year and to 40% at three years was documented during subsequent individual home-based training. Poor compliance thus remains a major challenge in the promotion of exercise training.

Except for one subject who revoked the informed consent before the first administration, no other subject in the WS 1442 groups exhibited major treatment compliance problems. Nevertheless, compliance has also been identified as a relevant issue in preventive pharmacotherapy, as demonstrated in the EUROASPIRE trials ([@r40]). Current guidelines and recommendations suggest physical exercise training and dietary measures in otherwise healthy individuals who are overweight but not obese, whereas pharmacological treatment is only recommended if comorbidities are already present ([@r2], [@r41]). Individuals at risk of CVD may nevertheless prefer a drug over lifestyle modification, or they may not be able to exercise due to physical disability. In such cases, WS 1442 may be a viable option if a prophylactic and therapeutic effect on endothelial function can be confirmed in this population.

The main limitation of our study was the small sample size. It is the nature of a pilot study that it is only hypothesis-generating and does not provide definite answer to the research question proposed.

The results of this pilot study indicated that *Crataegus* extract WS 1442 might have a beneficial effect on the lipid profile and endothelial function, similar to the effects of regular exercise training, and without signals of unwanted effects. Nonetheless, beneficial changes in exercise capacity could only be achieved through exercise training. Although the results of this small-sample pilot study should be interpreted cautiously and the comparison between WS 1442 and NW may have been biased by coincidental baseline imbalance, it may nevertheless be worthwhile to further investigate the potential of the extract as a preventive tool in the armamentarium against the development of CVD in overweight, inactive, yet otherwise healthy individuals.
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